MOREPENLAB — Morepen Laboratories Balance Sheet
0.000.00%
- IN₹37.30bn
- IN₹37.28bn
- IN₹16.90bn
- 62
- 26
- 94
- 69
Annual balance sheet for Morepen Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 136 | 414 | 158 | 217 | 313 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1,534 | 2,126 | 2,913 | 2,978 | 3,252 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,722 | 5,268 | 7,343 | 7,562 | 8,890 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,341 | 1,312 | 1,608 | 1,840 | 2,377 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 6,635 | 8,581 | 10,701 | 11,105 | 12,932 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,514 | 4,038 | 4,565 | 3,212 | 4,020 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 3,794 | 4,334 | 4,915 | 3,576 | 4,460 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 2,841 | 4,247 | 5,786 | 7,529 | 8,472 |
Total Liabilities & Shareholders' Equity | 6,635 | 8,581 | 10,701 | 11,105 | 12,932 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |